SPOTLIGHT: NHS approves drugs


British patients on the National Health Service will get access to two intensive arthritis therapies: MabThera, made by Roche; and Humira, made by Abbott Laboratories. Patient advocacy groups have been lobbying for the drugs since the National Institute for Health and Clinical Excellence (NICE) refused to add Orencia, a similar medication, to the NHS formulary. Release 

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.